A generic alternative indicated for Antivirals. Therapy interrupts the replication cycle of the hepatitis C virus to support long-term liver resilience.
A combined antiviral medication developed to manage chronic Hepatitis C and formulated to alleviate liver damage by targeting viral replication to support a cure.
Mechanism of Action
Ledipasvir inhibits the NS5A protein, and sofosbuvir inhibits the NS5B polymerase. Together, they prevent the Hepatitis C virus from making copies of its genetic material.
Route of Administration
Oral
Onset Time
Steady state in days
Duration
24 hours
Contraindications
Allergy to ledipasvir or sofosbuvir
Severe Adverse Events
Hepatitis B reactivation, Severe slow heart rate (with amiodarone), Liver toxicity, Severe allergic reaction
Common Side Effects
Fatigue, Headache
Uncommon Side Effects
Nausea, Insomnia, Diarrhea, Dizziness
Drug Interactions
Amiodarone, Rifampin, St. John's wort, Antacids, Tenofovir
Information for Harvoni is sourced from established medical standards and updated frequently. It is provided for general reference and should be confirmed with a healthcare professional before use.
